Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
The 21-year-old, who was arrested on Sunday, also allegedly injured two other people in the attack in the German city of Reutlingen.
She was going to the aid of a family member who got out of the car in the middle of the park and was dragged away by a different tiger.
The man, who was in his 30s, has not been identified, while several other people are believed to have suffered serious injuries.